[1]Jasińska-Stroschein M, Orszulak-Michalak D. Novel strategies for treatment of pulmonary arterial hypertension[J].Postepy Hig Med Dosw, 2017, 71(1):577.
[2]Madonna R, Cocco N. Novel strategies in the treatment of pulmonary arterial hypertension[J]. Curr Drug Targets, 2016, 17(7):817-823.
[3]Fallah F. Recent strategies in treatment of pulmonary arterial hypertension, a review[J].Glob J Health Sci, 2015, 7(4):307-322.
[4]Rubin L, Badesch D, Barst R, et al. Bosentan therapy for pulmonary arterial hypertension.[J]. Acc Curr J Rev, 2002, 11(5):30-30.
[5]Ch.P (2015) Vol Ⅳ (中国药典2015年版四部) [S]. 2015: 356-362.
[6]国家药品监督管理局. 以药动学参数为终点评价指标的化学药物仿制药人体生物等效性研究技术指导原则[EB/OL]. (2016-03-18)[2016-03-21].www.nmpa.gov.cn/WS04/CL2138/300138.html.
[7]Yokoyama Y, Tomatsuri M, Hayashi H, et al. Simultaneous microdetermination of bosentan, ambrisentan, sildenafil, and tadalafil in plasma using liquid chromatography/tandem mass spectrometry for pediatric patients with pulmonary arterial hypertension.[J].J Pharm Biomed Anal, 2014, 89(4):227-232.
[8]Weber C, Schmitt R, Birnboeck H, et al. Pharmacokinetics and pharmacodynamics of the endothelin-receptor antagonist bosentan in healthy human subjects [J].Clin Pharmacol Ther, 1996, 60(2):124-137.
[9]Van G, Dingemanse J. Comparative investigation of the pharmacokinetics of bosentan in Caucasian and Japanese healthy subjects[J]. J Clin Pharmaco, 2013, 45(1):42-47.
[10]Parekh JM, Shah DK, Sanyal M, et al. Development of an SPE-LC-MS/MS method for simultaneous quantification of bosentan and its active metabolite hydroxybosentan in human plasma to support a bioequivalence study[J]. J Pharm Biomed Anal, 2012, 70(21):462-470.
[11]Qiu X, Zhao J, Wang Z, et al. Simultaneous determination of bosentan and glimepiride in human plasma by ultra performance liquid chromatography tandem mass spectrometry and its application to a pharmacokinetic study[J]. J Pharm Biomed Anal, 2014, 95(3):207-212.
[12]Galie N, Humbert M, Vachiery JL, et al. 2015 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension: the Joint Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS): Endorsed by: Association for European Paediatric and Congenital Cardiology (AEPC), International Society for Heart and Lung Transplantation (ISHLT)[J]. Eur Respir J, 2015,46(4):903-975. |